New data revealed that after four years of continuous treatment, over 70% of patients with psoriasis achieved a 75% reduction in disease severity, known as PASI 75, in a long-term extension trial of Sotyktu. Similarly, around 57% achieved clear or almost clear skin, based on the static Physician’s Global Assessment (sPGA).
The safety profile of Sotyktu remained consistent throughout the four years, with no new safety concerns identified. In the extension trial, 513 patients received continuous Sotyktu treatment and showed sustained clinical efficacy. PASI 75 response rates stayed above 70%, PASI 90 response rates remained around 47%, and sPGA 0/1 response rates were over 57% at the end of year four.
The safety analysis included over 1,500 patients who received Sotyktu for at least four years. The incidence rates of adverse events, serious adverse events, and discontinuations due to adverse events decreased or remained stable compared to the first year of treatment. The rates of herpes zoster, malignancies, major adverse cardiovascular events, venous thromboembolism, and deaths remained low and consistent throughout the four years.
These findings suggest that Sotyktu is a safe and effective long-term treatment for adults with moderate-to-severe plaque psoriasis, providing sustained disease control and a favorable safety profile.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.